Panagiotis Tasoudis

Dr. Panagiotis Tasoudis

University of Thessaly
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2022 in Structural Heart
Verified
Journal Article
Open access
MSMichel Pompeu B.O. Sá
Michel Pompeu B.O. Sá
XJXander Jacquemyn
Xander Jacquemyn
Jef Van den EyndeJef Van den Eynde
Jef Van den Eynde
Panagiotis TasoudisPanagiotis Tasoudis
Panagiotis Tasoudis
OEOzgun Erten
Ozgun Erten
BRBasel Ramlawi
Basel Ramlawi
Paravalvular leak (PVL) after transcatheter aortic valve implantation (TAVI) is frequent and the impact of mild PVL on outcomes remains uncertain. Our study aimed to evaluate the impact of PVL on TAVI outcomes. To analyze late outcomes of patients after TAVI according to the presence and severity of PVL, PubMed/MEDLINE, EMBASE and Google Scholar were searched for studies that reported rates of all-cause mortality/survival and/or rehospitalization and/or cardiovascular mortality accompanied by at least one Kaplan-Meier curve for any of these outcomes. We adopted a 2-stage approach to reconstruct individual patient data based on the published Kaplan-Meier graphs. Thirty-eight studies with Kaplan-Meier curves met our eligibility criteria including over 25,000 patients. Patients with any degree of PVL after TAVI had a significantly higher risk of overall mortality (hazard ratio (HR), 1.52; 95% confidence interval (CI), 1.43-1.61; p < 0.001), rehospitalization (HR, 1.81; 95% CI, 1.54-2.12; p < 0.001), and cardiovascular mortality (HR, 1.52; 95% CI, 1.33-1.75; p < 0.001) over time. These findings remained consistent when we stratified the results for the methods of assessment of PVL (i.e., echocardiography vs. angiography) and PVL severity. Both moderate/severe PVL and mild PVL were associated with increased risk of overall mortality (p < 0.001), rehospitalization (p < 0.001), and cardiovascular mortality (p < 0.001) during follow-up. Patients with PVL, even if mild, experience higher risk of all-cause mortality, rehospitalization, and cardiovascular mortality following TAVI. These findings provide support to the implementation of procedural strategies to prevent any degree of PVL at the time of TAVI.

21 April 2022 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Open access
Panagiotis TasoudisPanagiotis Tasoudis
Panagiotis Tasoudis
DVDimitrios N Varvoglis
Dimitrios N Varvoglis
EVEvangelos Vitkos
Evangelos Vitkos
KMKonstantinos S Mylonas
Konstantinos S Mylonas
MSMichel Pompeu Sá
Michel Pompeu Sá
Thanos AthanasiouThanos Athanasiou
Thanos Athanasiou
OBJECTIVES: The aim of this study was to compare biological versus mechanical aortic valve replacement. METHODS: We searched MEDLINE, Scopus and Cochrane Library databases for randomized clinical trials and propensity score-matched studies published by 14 October 2021 according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement. Individual patient data on overall survival were extracted. One- and two-stage survival analyses and random-effects meta-analyses were conducted. RESULTS: A total of 25 studies were identified, incorporating 8721 bioprosthetic and 8962 mechanical valves. In the one-stage meta-analysis, mechanical valves cumulatively demonstrated decreased hazard for mortality [hazard ratio (HR): 0.79, 95% confidence interval (CI): 0.74–0.84, P < 0.0001]. Overall survival was similar between the compared arms for patients <50 years old (HR: 0.88, 95% CI: 0.71–1.1, P = 0.216), increased in the mechanical valve arm for patients 50–70 years old (HR: 0.76, 95% CI: 0.70–0.83, P < 0.0001) and increased in the bioprosthetic arm for patients >70 years old (HR: 1.35, 95% CI: 1.17–1.57, P < 0.0001). Meta-regression analysis revealed that the survival in the 50–70 year-old group was not influenced by the publication year of the individual studies. No statistically significant difference was observed regarding in-hospital mortality, postoperative strokes and postoperative reoperation. All-cause mortality was found decreased in the mechanical group, cardiac mortality was comparable between the 2 groups, major bleeding rates were increased in the mechanical valve group and reoperation rates were increased in the bioprosthetic valve group. CONCLUSIONS: Survival rates seem to not be influenced by the type of prosthesis in patients 70 years old bioprosthetic valves offer better survival outcomes.

14 September 2022 in American Heart Journal
Verified
Journal Article
Closed access
KMKonstantinos S. Mylonas
Konstantinos S. Mylonas
Panagiotis TasoudisPanagiotis Tasoudis
Panagiotis Tasoudis
DPDionysios Pavlopoulos
Dionysios Pavlopoulos
MKMeletios Kanakis
Meletios Kanakis
GSGeorge T. Stavridis
George T. Stavridis
DADimitrios V. Avgerinos
Dimitrios V. Avgerinos

13 August 2022 in Journal of the Society for Cardiovascular Angiography & Interventions
Verified
Journal Article
Open access
MSMichel Pompeu B.O. Sá
Michel Pompeu B.O. Sá
XJXander Jacquemyn
Xander Jacquemyn
TSTian Sun
Tian Sun
Jef Van den EyndeJef Van den Eynde
Jef Van den Eynde
Panagiotis TasoudisPanagiotis Tasoudis
Panagiotis Tasoudis
BRBasel Ramlawi
Basel Ramlawi
Permanent pacemaker implantation (PPI) after transcatheter aortic valve replacement (TAVR) is relatively frequent, and its impact on outcomes during follow-up remains a matter of discussion. Previous meta-analyses have yielded conflicting results. To compare late outcomes in patients after TAVR with and without PPI, PubMed/MEDLINE, Embase, and Google Scholar were searched for studies that reported rates of mortality/survival, rehospitalization for heart failure (HF), stroke, and/or endocarditis accompanied by at least 1 Kaplan-Meier curve for any of these outcomes. We adopted a 2-stage approach to reconstruct individual patient data on the basis of the published Kaplan-Meier graphs. Twenty-eight studies with Kaplan-Meier curves met our eligibility criteria and included a total of 50,282 patients (7232 who underwent PPI and 42,959 who did not undergo PPI). Patients who underwent PPI after TAVR had a significantly higher risk of mortality (hazard ratio [HR], 1.21; 95% CI, 1.14-1.28; P < .001) and HF-related rehospitalization (HR, 1.30; 95% CI, 1.17-1.45; P < .001) over time. We did not observe statistically significant differences in the incidence of stroke (HR, 1.07; 95% CI, 0.55-2.08; P = .849) and endocarditis (HR, 0.98; 95% CI, 0.61-1.57; P = .925) during follow-up. Patients who undergo PPI after TAVR experience higher risk of mortality and HF-related rehospitalization over time. These findings provide support for the implementation of procedural strategies to prevent heart conduction disorder and, thus, avoid PPI at the time of TAVR.

1 October 2023 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
Panagiotis TasoudisPanagiotis Tasoudis
Panagiotis Tasoudis
JDJ. Nathaniel Diehl
J. Nathaniel Diehl
AMAurelie Merlo
Aurelie Merlo
JLJason M. Long
Jason M. Long
Background: Video-assisted thoracoscopic surgery (VATS) and robotic-assisted thoracoscopic surgery (RATS) are two viable options in patients undergoing lobectomy for non-small cell lung cancer (NSCLC); however, the debate on which one is superior is unceasing. Methods: PubMed and Scopus databases were queried for studies including patients who underwent either VATS or RATS lobectomy. This meta-analysis is in accordance with the recommendations of the PRISMA statement. Individual patient data on overall survival (OS) and disease-free survival (DFS) were extracted from Kaplan-Meier curves. One- and two-stage survival analyses, and random-effects meta-analyses were conducted. Results: Ten studies met our eligibility criteria, incorporating 1,231 and 814 patients in the VATS and RATS groups, respectively. Patients who underwent VATS had similar OS compared with those who underwent RATS [hazard ratio (HR): 1.05, 95% confidence interval (CI): 0.88–1.27, P=0.538] during a weighted median follow-up of 51.7 months, and this was validated by the two-stage meta-analysis (HR: 1.27, 95% CI: 0.85–1.90, P=0.24, I2=68.50%). Regarding DFS, the two groups also displayed equivalent outcomes (HR: 1.07, 95% CI: 0.92–1.25, P=0.371) and this was once again validated by the two-stage meta-analysis (HR: 1.05, 95% CI: 0.85–1.30, P=0.67, I2=28.27%). Both RATS and VATS had similar postoperative complication rates, prolonged air leak, conversion to thoracotomy and operative times. RATS was found to be superior to VATS in terms of length of hospital stay and number of lymph nodes dissected. Conclusions: In patients undergoing lobectomy for NSCLC, VATS and RATS have equivalent overall and DFS at a median follow-up of 51.7 months.

10 September 2022 in Journal of Cardiac Surgery
Verified
Journal Article
Closed access
MSMichel Pompeu B.O. Sá
Michel Pompeu B.O. Sá
XJXander Jacquemyn
Xander Jacquemyn
Panagiotis TasoudisPanagiotis Tasoudis
Panagiotis Tasoudis
Jef Van den EyndeJef Van den Eynde
Jef Van den Eynde
OEOzgun Erten
Ozgun Erten
BRBasel Ramlawi
Basel Ramlawi